| Name |
AbstractNr. |
Title |
| Jansen |
18 |
Increasing trend in HIV-1 incidence among young men who have sex with men in Amsterdam: a 25-year prospective cohort study |
| van Veen |
19 |
Sexually transmitted infections in HIV-infected attendees of STI clinics |
| van den Boom |
20 |
Are we systematically overestimating rates of sexual risk with casual partners among men who have sex with men? |
| Xiridou |
21 |
Do migrants from HIV-endemic countries affect the heterosexual transmission of HIV in the Netherlands? |
| Op de Coul |
22 |
Effectiveness of antenatal screening for HIV, hepatitis B and syphilis in the Netherlands |
| van Sighem |
23 |
Estimating the number of people living with HIV/AIDS in the Netherlands |
| van Veen |
24 |
National estimate of HIV prevalence in the Netherlands: comparison and applicability of different estimation tools |
| Kesselring |
25 |
Immunodeficiency is a risk factor for non-AIDS defining malignancies in HIV-1 infected patients on combination antiretroviral therapy. |
| Gras |
26 |
Serious non-AIDS events are increasingly more common than AIDS events in the HIV-1 cART treated population |
| van der Helm |
27 |
The hepatitis C epidemic among HIV-positive men who have sex with men started before 2000 |
| Welling |
28 |
Significant increase in the number of HIV-infected homosexual men, co-infected with hepatitis C. |
| Jong |
29 |
Screening of HIV-infected MSM for anal dysplasia by anal cytology, proctoscopy and detection of human papillomavirus DNA |
| van Sighem |
30 |
Life expectancy of recently diagnosed asymptomatic HIV-infected patients approaches that of uninfected individuals |
| Barth |
31 |
Long Term Follow Up of ART in a Pediatric Cohort in Rural South Africa; Virologic Failure on First Line Treatment |
| Sonder |
32 |
Comparison Of Two Hiv-Pep Regimens Among Msm In Amsterdam Reveals Side Effects Do Not Influence Compliance |
| Euler |
33 |
Cross-reactive neutralizing humoral immunity does not protect from HIV-1 disease progression |
| Boer |
34 |
The effectiveness of national first trimester opt-out HIV screening in the Netherlands |
| Fillekes |
35 |
Prevention Mother-To-Child Transmission Hiv-1: the effect of single sose Carbamazepine on pharmacokinetics of single dose Nevirapine |
| Lambers |
36 |
Limited knowledge about HCV among MSM from the Amsterdam Cohort Studies |
| Zuure |
37 |
Use of self-tests for HIV and sexually transmitted infections (STI) among the population of Amsterdam |
| Bouwhuis |
38 |
Development of a generalizable measurement tool to evaluate HIV/AIDS education training programs |
| Stax |
39 |
Mucin 6 in seminal plasma binds DC-SIGN and blocks HIV-1 transfer via dendritic cells |
| Schellens |
40 |
HLA-related protection against progression to AIDS: a different mechanism for HLA-B27 and HLA-B57 |
| Fabrice Rene |
41 |
T- Lymphocytes Activation and Baseline Resistance in HIV infected patients ready to start HAART in Burkina Faso (West Africa) |
| Heeregrave |
42 |
HIV-1 infection and evolution within CD4+ T cell subsets in vivo & the influence of TB co-infection |
| Goede |
43 |
HIV-1 sequence evolution after dendritic cell-based immune therapy in a phase I/II clinical trial |
| Bol |
44 |
Discovery of common genetic variants associated with in vitro HIV-1 replication in monocyte-derived macrophages |
| van Gils |
45 |
Rapid escape of HIV-1 from longitudinally preserved autologous serum neutralizing activity with potent cross-reactivity |
| Gras |
46 |
Viral load levels measured at set-point have risen over the last decade of the HIV epidemic in the Netherlands |
| Pasternak |
47 |
Intracellular HIV-1 unspliced RNA: a disease progression marker in untreated patients and a predictive marker of virological rebound in cART-treated patients with undetectable plasma viremia |
| Burger |
48 |
Changes in efavirenz plasma concentrations in HIV-infected patients who switch from Stocrin® to Atripla® |
| de Kanter |
49 |
Pharmacokinetics of 2 generic co-formulations of lopinavir/ritonavir for HIV-infected children: pilot of pediatric Lopimune formulations vs. branded product (healthy volunteers) |
| Jansen |
50 |
Clinical experience with raltegravir once-daily in combination with unboosted atazanavir |
| Hermanides |
51 |
The effect of antiretroviral therapy in HIV-1-infected treated in Curacao compared with Antillean, Surinamese & Dutch populations treated in the Netherlands |
| Mudrikova |
52 |
Factors associated with non-adherence to outpatient clinic appointments by HIV infected patients |
| Frentz |
53 |
Comparison of HIV-1 Genotypic Resistance Test Interpretation Systems in Predicting Virological Outcomes over Time. |
| Hamers |
54 |
Prevalence of Drug-resistant HIV-1 Variants at Initiation of Standard First-line HAART in Africa |
| Fun |
55 |
Resistance Mutations in the Viral Protease Alter the In Vitro Resistance Profiles of Bevirimat |
| van Lelyveld |
56 |
Comparison of Trofile, MT-2 assay and clinical outcome of maraviroc containing therapy |
| Dijk |
57 |
Inhibition of NFkB-mediated HIV-1 production in vitro by pectin derived galacturonic acid-based oligosaccharides seems to be dependent on polymerisation grade of the oligosaccharide. |
| van Lelyveld |
58 |
ICU mortality, in-hospital mortality as well as long term follow-up outcomes are significantly improved in HIV infected patients admitted to ICU in the HAART era |
| Arends |
59 |
High rate of non-response and relapse associated with peginterferon-alfa monotherapy for the treatment of acute hepatitis C in HIV infected patients |
